EUCTR2013-001113-32-DE进行中（未招募）不适用
A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the Post-anesthesia Care Unit / Intensive Care Unit
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients scheduled for major elective cardiac surgery, i.e. surgery assumed to require more than 2 hours of maintenance of general anesthesia and to require the use of extracorporeal circulation, including coronary bypass(es), valve replacement and surgery of the aortic arch
- •Scheduled to receive mechanical ventilation via tracheal intubation (oropharyngeal or nasotracheal)
- •Age at least 18 years
- •Weight between 55 and 150 kg inclusive
- •Body Mass Index (BMI) 18 to = 35 kg/m2
- •Willingness and ability to give informed consent, to understand, participate and comply with all study requirements
- •For women with childbearing potential: negative pregnancy test
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 54
排除标准
- •Thoraco-abdominal replacement of the aorta or other procedure expected to be accompanied by a massive hemorrhage (at least 15% of the circulating blood volume)
- •History of or planned cooling below 34ºC
- •History of or planned stop of circulation, e.g. due to repair of type A dissection of aorta or removal of thrombi from pulmonary artery
- •Planned to receive epidural/spinal anesthesia together with general anesthesia
- •Evidence of uncontrolled hepatic, central nervous system, respiratory, or metabolic dysfunction, or other clinically significant findings at screening that, in the investigator’s or medical monitor’s opinion, should exclude them from the study.
- •Poorly controlled hypertension (e.g. systolic blood pressure =160 mmHg under antihypertensive medication)
- •Severe renal insufficiency or end-stage renal disease (estimated glomerular filtration rate below 30 mL/min/1.73 m2)
- •Clinically uncontrolled coagulation abnormalities, or coagulation abnormalities not under adequate treatment
- •Total bilirubine =3.0 mg/dL or AST and/or ALT =2.5 x ULN during 7 days prior to starting administration of the investigational product
- •Scheduled for heart or lung transplantation
- •Infectious cardiac disorders (e.g. endocarditis, myocarditis)
- •Emergency surgery, status of shock or coma
- •Ejection fraction of less than 20%
- •Acute right heart failure
- •Pre-operative use of phosphodiesterase 3 inhibitors
- •History of resuscitation
- •Known resistance to benzodiazepines or history of paradoxical effects after administration of benzodiazepines
- •History of hypersensitivity to benzodiazepines, propofol, remifentanil hydrochloride, rocuronium bromide, flumazenil or other anesthetic agents
- •Use of benzodiazepines within 5 times their half-life or 5 times the half-life of their active metabolites. Exception: Single dose pre-medication before the surgery according to local standards is allowed.
- •Myasthenia gravis or myasthenic syndrome
- •History of any severe allergy
- •Dependence from alcohol or drugs or history of alcohol or drug abuse
- •Acute alcoholic intoxication or ethanol intake within 48 hours prior to surgery
- •Acute narrow-angle glaucoma
- •Female patients of childbearing potential without acceptable method of birth control or not surgically sterile
- •Pregnant or breast feeding female patients
- •Patients in receipt of any investigational drug within 30 days or less than 7 half-lives (whichever was longer) before the start of the study , or scheduled to receive one during the study period
- •Administration of remimazolam in the past
- •Unable to communicate well with the investigator
- •Other reasons that, according to the investigator, exclude the patient from the trial
研究者
相似试验
进行中（未招募）
不适用
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing ChemotherapyEUCTR2008-004429-41-NLBayer Healthcare AG, D-51368 Leverkusen, Germany250
已完成
2 期
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing ChemotherapyPeritoneal Cancer and Ovarian Cancer10033283NL-OMON33786Bayer20
进行中（未招募）
不适用
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing Chemotherapy - NDEUCTR2008-004429-41-ITBayer Healthcare AG250
进行中（未招募）
不适用
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing ChemotherapyThe study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete response (disappearance of all clinical and radiological evidence of tumor) after one regimen of standard platinum/taxane-based chemotherapy for whom treatment with sorafenib is considered medically acceptable.MedDRA version: 9.1Level: LLTClassification code 10033163Term: Ovarian epithelial cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10033164Term: Ovarian epithelial cancer stage IVMedDRA version: 9.1Level: LLTClassification code 10052171Term: Peritoneal carcinomaMedDRA version: 9.1Level: PTClassification code 10052171Term: Peritoneal carcinomaEUCTR2008-004429-41-DEBayer Healthcare AG250
进行中（未招募）
不适用
A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing ChemotherapyThe study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete response (disappearance of all clinical and radiological evidence of tumor) after one regimen of standard platinum/taxane-based chemotherapy for whom treatment with sorafenib is considered medically acceptable.MedDRA version: 9.1Level: LLTClassification code 10033163Term: Ovarian epithelial cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10033164Term: Ovarian epithelial cancer stage IVMedDRA version: 9.1Level: LLTClassification code 10052171Term: Peritoneal carcinomaMedDRA version: 9.1Level: PTClassification code 10052171Term: Peritoneal carcinomaEUCTR2008-004429-41-FIBayer Healthcare AG, D-51368 Leverkusen, Germany250